January 02, 2019
1 min read

First year LAMP results: 0.05% atropine reduces myopic progression

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In the first phase of the ongoing four-phase LAMP study, researchers report 0.05% atropine was most effective among three concentrations and placebo in controlling spherical equivalent and axial length in children with myopia.

The treatment phase of the Low-concentration Atropine for Myopia Progression (LAMP) double-masked study randomized 438 children aged 4 to 12 years to receive 1:1:1:1 either low dose atropine eye drops at concentrations of 0.05%, 0.025% or 0.01% or placebo eye drops in both eyes daily for 12 months.

A total of 383 participants were evaluated at the 1-year mark. Mean change in spherical equivalent was –0.27 D in the 0.05% atropine group, –0.46 D in the 0.025% group, –0.59 D in the 0.01% group and –0.81 D in the placebo group.

Axial elongation increased most in the placebo group, with 37.1% of eyes progressing 1 D or more compared with 15.2%, 12.6% and 27.8% of eyes in the 0.05%, 0.025% and 0.01% atropine groups, respectively. Furthermore, only 24.2% of eyes in the placebo group progressed less than 0.5 D, compared with 69.6%, 51.6% and 43.8% in the three atropine groups, respectively.

“Our results altogether have provided new evidence for low-concentration atropine as an effective and safe intervention against myopia progression,” the researchers said.

The second phase of the study will involve a cross-over of patients in the placebo group into the optimal treatment group, then continuation of atropine treatment to evaluate efficacy and side effects at 2 years. – by Patricia Nale, ELS

Disclosures: The authors report no relevant financial disclosures.